Clinical Trial Update: Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [NA]

View source ↗

Summary

A recruiting study is evaluating the safety and efficacy of Anti-BCMA-GPRC5D CAR-T cell therapy for relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-BCMA-GPRC5D CAR-T Cells Therapy

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: Relapsed/Refractory Multiple Myeloma | NA | Status: RECRUITING